Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
c-Met-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "c-Met-IN-1" in MCE Product Catalog:
Cat. No.: HY-101031
CAS No.: 2084836-84-8
Target:
Research Areas:
c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity. [1].
1
1 Cited Publications
Target:
Research Areas:
c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC50 of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma [1].
Synonyms: ANG-3777
Target:
Research Areas:
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .
Target:
Research Areas:
AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively .
Cat. No.: HY-168135
CAS No.: 3056647-52-7
Target:
Research Areas:
PROTAC c-Met degrader-1 is a selective and orally active c-Met PROTAC degrader with a DC50 of 6.21 nM against c-Met. PROTAC c-Met degrader-1 induces CRBN-dependent ubiquitination and proteasomal degradation of c-Met. PROTAC c-Met degrader-1 induces G0/G1 phase arrest in c-Met-dependent cancer cells. PROTAC c-Met degrader-1 kills c-Met-dependent cancer cells. PROTAC c-Met degrader-1 inhibits tumor growth in animal models. PROTAC c-Met degrader-1 can be used for the research of gastric cancer [1].
Cat. No.: HY-124761
CAS No.: 683808-78-8
Target:
Research Areas:
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .
Cat. No.: HY-P991664
Research Areas:
Cat. No.: HY-178438
CAS No.: 3062159-91-2
Target:
Research Areas:
Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer [1].
Cat. No.: HY-163006
CAS No.: 3020728-68-8
Target:
Research Areas:
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of EGFR/c-Met. The IC50 for inhibiting EGFR L858R and c-Met is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo [1].
Cat. No.: HY-149674
CAS No.: 3017162-02-3
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and c-Met with IC50s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity [1].
Cat. No.: HY-161372
CAS No.: 2944101-99-7
Target:
Research Areas:
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and c-Met, with IC50s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice [1].
Cat. No.: HY-P991565
Target:
Research Areas:
Cat. No.: HY-162679
Target:
Research Areas:
c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors [1].
Cat. No.: HY-120661
CAS No.: 1195779-24-8
Target:
Research Areas:
T-1840383 is a potent, ATP-competitive inhibitor of c-Met/VEGFR-2, with the IC50s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2 and VEGFR3, respectively [1].
Cat. No.: HY-162803
Target:
Research Areas:
c-Met-IN-24 (compound 3g) is a dual-target inhibitor of STAT-3 ( [1]=4.7 μM) and c-MET ( =12.67 μM) with anticancer activity. c-Met-IN-24 arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells. c-Met-IN-24 can be used in the study of central nervous system cancers [1].
Cat. No.: HY-W425461
CAS No.: 1103506-79-1
Research Areas:
c-Met ligand-1 is a c-Met ligand and component of c-Met PROTAC degrader (HY-175320) [1].
Cat. No.: HY-P11863
Target:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
